gene therapy

JPMorgan Upgrades Solid Biosciences Stock, Sees Growth Potential

JPMorgan upgraded Solid Biosciences stock, a biotechnology company that acquired UF startup AavantiBio, from Neutral to Overweight, and increased the price target to $15.00 from the previous $10.00. The firm's decision reflects a positive outlook on the company's prospects, particularly with upcoming developments expected in the fourth quarter.

Ascend Acquires Beacon Gene Therapy Manufacturing Site

Ascend Advanced Therapies, a gene therapy development partner, has purchased Beacon Therapeutics’ contract, manufacturing, and controls team—along with the company's site, previously owned by UF Innovate | Accelerate graduate AGTC, located in Alachua, FL—a town considered to be a “biotech hub” in the state. The acquisition introduces a good manufacturing practice (GMP) plant into the fold, along with process and analytical development capabilities.

Genascence to Present Full Data from Phase 1 Clinical Trial on GNSC-001, Company’s Lead Program in Osteoarthritis, at European Society of Gene & Cell Therapy 30th Annual Congress

Genascence Corporation, a clinical-stage biotechnology company revolutionizing the treatment of prevalent musculoskeletal diseases with gene therapy using technology discovered at the University of Florida, announced that data from the Phase 1 clinical trial of GNSC-001 for the treatment of osteoarthritis (OA) demonstrated that it was safe and well tolerated. 

Dr. Barry Byrne Named Innovator of the Year 

The annual event honored Dr. Barry Byrne as Innovator of the Year for his contributions to gene therapy and highlighted six teams of inventors for their Inventions of the Year. 

Myrtelle Enters Into a Worldwide Exclusive License Agreement With Rescue Hearing To Develop and Commercialize Gene Therapy for the Treatment of Hearing Loss

Myrtelle Inc., a clinical stage gene therapy company focused on developing transformative treatments for rare genetic diseases, today announced that it has entered into a worldwide exclusive licensing agreement with UF Innovate | Accelerate at The Hub alum Rescue Hearing Inc. (RHI) to develop a novel gene therapy for DFNB8 genetic hearing loss.

AavantiBio and Resilience Announce Strategic Collaboration for Gene Therapy Development and Manufacturing

UF startup and UF Innovate | The Hub resident AavantiBio, a gene therapy company focused on transforming the lives of patients with rare genetic diseases, and National Resilience, Inc. (Resilience), a company building the world’s most advanced biopharmaceutical manufacturing ecosystem and who recently acquired UF startup and UF Innovate | Sid Martin Biotech alum Ology Bioservices, announced a strategic collaboration to support the development and manufacturing of AavantiBio’s pipeline of therapies, including its lead program in Friedreich’s Ataxia (FA).